UCB-derived ex vivo expanded stem and progenitor cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for UCB-derived ex vivo expanded stem and progenitor cells, covering 2022-04-27 to 2022-04-27. Get the full timeline:
Most recent: Clinical Trial Update: Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies [Phase 1, Phase 2]